Puma Biotechnology Inc PBYI could face a setback in the launch of its breast cancer drug neratinib, as the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, relayed a "negative trend vote" after a meeting with the biotech company.
The Analyst
Cowen analyst Chris Shibutani downgraded shares of Puma Biotech from Outperform to Market Perform and reduced the price target from $128 to $68.
The Thesis
The CHMP's communication suggests EU approval is unlikely and that additional steps need to be taken in order to obtain marketing approval in the EU, Shibutani said in a Wednesday note. (See the analyst's track record here.)
Shibutani expects a negative outcome from the formal CHMP vote scheduled to take place in February, but said Puma Biotech could still appeal the decision. The likelihood of a reversal of a negative decision is low in the absence of a commitment to and/or production of data from an additional clinical trial, he said.
Cowen does not project a similar negative outcome for the drug in the rest of the world, but remains cautious on the prospects, Shibutani said.
The absence of EU approval will likely make the M&A narrative more challenging for Puma, the analyst said. Cowen has modeled an EU approval and was expecting the company to rope in a partner, with the former receiving royalties on sales, he said.
Cowen is removing adjuvant sales outside the U.S. from its forecast, but leaving U.S. — including metastatic — projections intact.
The Price Action
Puma Biotech shares were up about 192 percent over the past year ahead of Tuesday's announcement.
Shares were down 28.11 pecent at $65.35 at the time of publication Wednesday morning.
Related Links:
Attention Biotech Investors: Brace For These January PDUFA Events
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.